Journal Article

DKFZ-2017-01183

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.

Jaramillo, S. ; Benner, A.DKFZ* ; Krauter, J. ; Martin, H. ; Kindler, T. ; Bentz, M. ; Salih, H. R. ; Held, G. ; Köhne, C.-H. ; Götze, K. ; Lübbert, M. ; Kündgen, A. ; Brossart, P. ; Wattad, M. ; Salwender, H. ; Hertenstein, B. ; Nachbaur, D. ; Wulf, G. ; Horst, H.-A. ; Kirchen, H. ; Fiedler, W. ; Raghavachar, A. ; Russ, G. ; Kremers, S. ; Koller, E. ; Runde, V. ; Heil, G. ; Weber, D. ; Göhring, G. ; Döhner, K. ; Ganser, A. ; Döhner, H. ; Schlenk, R. (Last author)DKFZ*

2017
Nature Publishing Group London [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/bcj.2017.45

Abstract: The aim of this cohort study was to compare a condensed schedule of consolidation therapy with high-dose cytarabine on days 1, 2 and 3 (HDAC-123) with the HDAC schedule given on days 1, 3 and 5 (HDAC-135) as well as to evaluate the prophylactic use of pegfilgrastim after chemotherapy in younger patients with acute myeloid leukemia in first complete remission. One hundred and seventy-six patients were treated with HDAC-135 and 392 patients with HDAC-123 with prophylactic pegfilgrastim at days 10 and 8, respectively, in the AMLSG 07-04 and the German AML Intergroup protocol. Time from start to chemotherapy until hematologic recovery with white blood cells >1.0 G/l and neutrophils >0.5 G/l was in median 4 days shorter in patients receiving HDAC-123 compared with HDAC-135 (P<0.0001, each), and further reduced by 2 days (P<0.0001) by pegfilgrastim. Rates of infections were reduced by HDAC-123 (P<0.0001) and pegfilgrastim (P=0.002). Days in hospital and platelet transfusions were significantly reduced by HDAC-123 compared with HDAC-135. Survival was neither affected by HDAC-123 versus HDAC-135 nor by pegfilgrastim. In conclusion, consolidation therapy with HDAC-123 leads to faster hematologic recovery and less infections, platelet transfusions as well as days in hospital without affecting survival.

---

Contributing Institute(s):

1. Biostatistik (C060)
2. Klinische Studienzentrale (G040)

Research Program(s):

1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2017

---

Database coverage:
; ; ; BIOSIS Previews ; Current Contents - Clinical Medicine ; DOAJ Seal ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection

---